When Tresiba® co-formulates with NovoRapid® ...

Your patients can experience the freedom# with Ryzodeg® - the first and only 2-in-1 insulin co-formulation providing basal and post-prandial control[1-5]

Ryzodeg® FlexTouch®
100 U/ml



Onset: 14 minutes
Duration: Beyond 24 hours

Ryzodeg® can be a convenient treatment that fits into type 2 diabetes patients' lives[1,6,7]

Once or twice daily dosing with main meal[1]

Targets both FPG and PPG for glycaemic control[1]

A flexible dosing regimen that can give patients the confidence to manage their treatment[1,6,11-13]

Ryzodeg® is ready to use[1]

No resuspension, rolling or shaking needed[1]



Ryzodeg® allows for flexibility

The duration of action of insulin aspart is 3-5 hours, therefore, an interval of 3-5 hours should be allowed between two doses of Ryzodeg®[8]

with flexibility in mealtime dose timing with the main meal(s)[1]

For Type 2 Diabetes - A simpler way to be smart about basal and bolus

In T2DM patients treated with basal insulin ± OADs and in need of treatment intensification, Ryzodeg® OD / BID, compared to insulin glargine U100 OD + insulin aspart OD / BID / TID (2-4 injections/day), demonstrated .....

Non inferior in HbA_{1C} reduction with less injections/day [7]



Significant lower insulin dose [7]



Significant lower rates of nocturnal hypoglycaemia [7]



Glucose-lowering effect of Ryzodeg® dosed twice daily [9]



Ryzodeg® BID represents an alternative to basal bolus regimens for patients who require bolus insulin but need a simplified insulin regimen to overcome commonly cited issues of complexity and inconvenience as barriers to basal bolus regimens[1,10]

*Round to the nearest integer. 1.62 and 2.85 mean injections per day at 38 weeks with Ryzodeg® OD/BID and IGlar U100 OD + IAsp OD/BID/TID respectively[7]
BID = 'Bis in die' (twice daily); CI = confidence interval; HbA_{1C} = glycated haemoglobin A1c; IAsp= insulin aspart; IGlar U100 = insulin glargine U100; NS = not significant; OD = once daily; TID = 'Ter in die' (thrice daily); T2DM = Type 2 Diabetes Mellitus; OAD = oral antidiabetic agent

References: 1. Ryzodeg® Summary of product insert. **2.** Vijan S, et al. J gen Intern Med. 2005;20(5):479-482. **3.** Fulcher G, et al. Diabetes Care. 2014;37(8):2084-2090. **4.** Haahr H, et al. Clin Pharmacokinet. 2017;56(4):339-354. **5.** Local IQVIA data. Q1 2020. **6.** Kumar A, et al. Int J Clin Pract. 2016;70(8):657-667. **7.** Philis-Tsimikas A, et al. Diabetes Res Clin Pract. 2019;147:157-165. **8.** NovoRapid® Summary of product insert. **9.** Heise T, et al. Diabetes Ther. 2014 Jun; 5(1): 255-265. **10.** H. W. Rodbard, et al. Diabetes ObesMetab. 2016;18(3):274-28. **11.** Peyrot M, et al. Diabetes Care. 2010;33(2): 240-245. **12.** Fujimoto K, et al. Diabetol Metab Synd. 2018;10:64. **13.** Kaneko S, et al. Diabetes Res Clin Pract. 2015;107(1):139-147.

novo nordisk®

Further information is available from:
Novo Nordisk Hong Kong Ltd
Unit 923A-928, 9/F, Trade Square, 681 Cheung Sha Wan Road, Kowloon, Hong Kong
Tel: (852) 3725 1300 Fax: (852) 2386 0800 www.novonordisk.com

RYZODEG®
70% insulin degludec and 30% insulin aspart [rDNA origin] injection

RYZ-D-20210301